Gregory Engel
Director/Board Member at Canadian Chamber of Commerce
Profile
Gregory Engel is currently a Director at the Canadian Chamber of Commerce and a Director at Clairvoyant Therapeutics, Inc. He was previously the Chief Executive Officer at Tilray Canada Ltd.
from 2015 to 2016, the Chief Executive Officer & Non-Independent Director at OrganiGram Holdings, Inc. from 2017 to 2021, and the General Manager at Forest Laboratories Canada, Inc. from 2010 to 2014.
He obtained an undergraduate degree from the University of Guelph.
Gregory Engel active positions
| Companies | Position | Start |
|---|---|---|
Canadian Chamber of Commerce
 Canadian Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services The Canadian Chamber of Commerce is a chamber of commerce organization. The non-profit company is based in Ottawa, Canada. | Director/Board Member | 2020-10-29 |
Clairvoyant Therapeutics, Inc.
 Clairvoyant Therapeutics, Inc. BiotechnologyHealth Technology Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The private company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022. | Director/Board Member | - |
Former positions of Gregory Engel
| Companies | Position | End |
|---|---|---|
| ORGANIGRAM HOLDINGS INC. | Chief Executive Officer | 2021-05-02 |
Tilray Canada Ltd.
 Tilray Canada Ltd. Pharmaceuticals: OtherHealth Technology Tilray Canada Ltd. provides ship medical cannabis to registered patients. The firm offers research and health policy, microbiology, plant genetics and drug development. The company is headquartered in Nanaimo, Canada. | Chief Executive Officer | 2016-05-31 |
Forest Laboratories Canada, Inc.
 Forest Laboratories Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., Forest Laboratories Canada, Inc. is a pharmaceutical company based in Saint John, Canada. | Corporate Officer/Principal | 2014-07-31 |
Training of Gregory Engel
| University of Guelph | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ORGANIGRAM HOLDINGS INC. | Process Industries |
| Private companies | 4 |
|---|---|
Canadian Chamber of Commerce
Canadian Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services The Canadian Chamber of Commerce is a chamber of commerce organization. The non-profit company is based in Ottawa, Canada. | Commercial Services |
Forest Laboratories Canada, Inc.
Forest Laboratories Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., Forest Laboratories Canada, Inc. is a pharmaceutical company based in Saint John, Canada. | Health Technology |
Tilray Canada Ltd.
Tilray Canada Ltd. Pharmaceuticals: OtherHealth Technology Tilray Canada Ltd. provides ship medical cannabis to registered patients. The firm offers research and health policy, microbiology, plant genetics and drug development. The company is headquartered in Nanaimo, Canada. | Health Technology |
Clairvoyant Therapeutics, Inc.
Clairvoyant Therapeutics, Inc. BiotechnologyHealth Technology Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The private company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022. | Health Technology |
- Stock Market
- Insiders
- Gregory Engel
